ClinicalTrials.gg
TerminatedNCT05517447Updated Apr 29, 2026

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

A Phase 3 interventional study of Observational cohort study and Batoclimab in Thyroid Eye Disease, sponsored by Immunovant Sciences GmbH. Terminated at 55 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Immunovant Sciences GmbH · Phase 3, Interventional, and Treatment

Why this study was terminated
The feeder studies (i.e., IMVT-1401-3201 and 3202) for study IMVT-1401-3203 failed to achieve their pre-defined primary efficacy outcomes. Accordingly, there was a change to the benefit-risk balance. No new safety findings were observed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
15th of 47
109 · median 84
Started
2022
with 4 others
Phase 3
21 of 53
3 open now
Registered
19th of 53
by date
Lead sponsor
4 of 53
Immunovant Sciences GmbH

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 15th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 19th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

03

Conditions studied

  • Thyroid Eye Disease

Keywords

  • Batoclimab
  • Thyroid eye disease
  • IMVT-1401
  • Monoclonal antibody
  • Autoimmune disorders
  • Graves' Ophthalmopathy
  • Graves' Orbitopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all participants:

1. Have completed the Week 24 visit of the feeder study.

For participants assigned to the Open-label Treatment Cohort:

  1. Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
  2. Did not permanently discontinue batoclimab

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion criteria:

For all participants:

1. In the Investigator's judgement, the benefits of entry in the study do not outweigh the risk.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Other
    Observational cohort

    Proptosis responders in feeder studies will enter in a non-treatment observational study

    Other: Observational cohort study

  • Experimental
    Treatment Cohort

    Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks

    Drug: Batoclimab

Interventions

  • OtherObservational cohort study

    Observational cohort study

  • Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

    Also known as: IMVT-1401

06

What researchers measure

Primary outcomes

  1. Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studies

    Time frame: Up to Week 24

Secondary outcomes

  1. Percentage of proptosis responders in study eye in placebo non-responder participants in the feeder studies

    Time frame: At Week 24

  2. Percentage of proptosis responders in study eye in batoclimab non-responder participants in the feeder studies

    Time frame: At Week 24

07

Study locations

55 sites
  • Site Number - 1520
    Glendora, California 91741, United States
  • Site Number - 1501
    Aurora, Colorado 80045, United States
  • Site Number - 1526
    Livonia, Michigan 48152, United States
  • Site Number - 1513
    Rochester, Minnesota 55905, United States
  • Site Number - 1540
    Las Vegas, Nevada 89184, United States
  • Site Number - 1508
    Houston, Texas 77030, United States
  • Site Number - 1558
    Mesquite, Texas 75149, United States
  • Site Number - 1511
    Morgantown, West Virginia 26506, United States
  • Site Number - 1518
    Milwaukee, Wisconsin 53226, United States
  • Site Number - 7565
    Sydney, 2000, Australia
  • Site Number - 4671
    Bruges, 8000, Belgium
  • Site Number - 4672
    Brussels, 1070, Belgium
  • Site Number - 4673
    Brussels, 1200, Belgium
  • Site Number - 4670
    Ghent, B-9000, Belgium
  • Site Number - 3454
    Tbilisi, 114, Georgia
  • Site Number - 3455
    Tbilisi, 114, Georgia
  • Site Number - 3450
    Tbilisi, 159, Georgia
  • Site Number - 3451
    Tbilisi, 159, Georgia
  • Site Number - 7550
    Budapest, 1133, Hungary
  • Site Number - 7552
    Pécs, 7623, Hungary
  • Site Number - 4760
    Ramat Gan, Tel Aviv 5265601, Israel
  • Site Number - 4764
    Afula, 1834111, Israel
  • Site Number - 4761
    Jerusalem, 91120, Israel
  • Site Number - 4762
    Petah Tikva, 4941492, Israel
  • Site Number - 6207
    Catania, CAP95125, Italy
  • Site Number - 6204
    Milan, 20122, Italy
  • Site Number - 6203
    Milan, 20149, Italy
  • Site Number - 6205
    Naples, 80131, Italy
  • Site Number - 6209
    Palermo, 90127, Italy
  • Site Number - 6201
    Pisa, 56124, Italy
  • Site Number - 6202
    Rome, 00189, Italy
  • Site Number - 9301
    Ogre, LV-5001, Latvia
  • Site Number - 9300
    Riga, LV-1006, Latvia
  • Site Number - 9302
    Ventspils, LV3601, Latvia
  • Site Number - 7570
    Christchurch, 8013, New Zealand
  • Site Number - 3107
    Gliwice, Silesian Voivodeship 44-102, Poland
  • Site Number - 3101
    Krakow, 30-688, Poland
  • Site Number - 3104
    Lublin, 20-171, Poland
  • Site Number - 3105
    Lublin, 60-354, Poland
  • Site Number - 1990
    San Juan, 00921, Puerto Rico
  • Site Number - 9200
    Bratislava, 82606, Slovakia
  • Site Number - 9201
    Bratislava, Slovakia
  • Site Number - 9202
    Trenčín, 91101, Slovakia
  • Site Number - 3602
    Barcelona, Catalonia 8006, Spain
  • Site Number - 3604
    Madrid, 28034, Spain
  • Site Number - 3600
    Santiago de Compostela, 15706, Spain
  • Site Number - 3606
    Seville, 41009, Spain
  • Site Number - 3603
    Valencia, 46026, Spain
  • Site Number - 7305
    Guildford, GU2 7XX, United Kingdom
  • Site Number - 7303
    London, EC1V 2PD, United Kingdom
  • Site Number - 7312
    London, W1T 6AH, United Kingdom
  • Site Number - 7313
    London, W1T 7HA, United Kingdom
  • Site Number - 7300
    Manchester, M139WL, United Kingdom
  • Site Number - 7302
    Newcastle upon Tyne, NE1 3BZ, United Kingdom
  • Site Number - 7308
    Sheffield, S102SB, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Apr 2026, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Nov 6, 2022
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05517447
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Nov 6, 2022
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Apr 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion